Chong Kun Dang Pharmaceutical Corp.
VC Fund
Seoul, South Korea
Chong Kun Dang Pharmaceutical Corp. is a Pharmaceutical company.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chong Kun Dang Pharmaceutical Corp. invests in
Stages Chong Kun Dang Pharmaceutical Corp. invests in
Countries Chong Kun Dang Pharmaceutical Corp. invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Therapeutics 2 (67%)
- FinTech 1 (33%)
- Medical 1 (33%)
- Biopharma 1 (33%)
Stage
- Series B 2 (67%)
- Series C 1 (33%)
Country
- South Korea 2 (67%)
- Israel 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BIORCHESTRA
|
BIORCHESTRA is a developer of RNA-based therapeutics. | $45.7M / Series C / Feb 22, 2022 | |
Nodit
|
Founded in 2012, Dunamu (CEO Lee Seok-woo) is currently providing services as the largest cryptocurrency exchange in Korea, 'Upbit' and stock trading platform based on social network, ‘Kakao Stock'. Both services are leading in the industry and ecosystems. (Upbit launched in Oct. 2017, Kakao Stock launched in Feb. 2014) Dunamuprovides the best service in the fields of cryptocurrency, securities, and asset management. Dunamu is getting much attention in both domestic and global market with professional specialists, innovative services and excellent technology. Recently, it announced to make investment of 100 billion dollars in the blockchain industry, leading the way in creating blockchain ecosystem. | $60M / Series B / Dec 15, 2021 | |
BIOMx
|
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $32M / Series B / Feb 20, 2019 |
Co-Investors
KB Investment
2 deals together
SBI Investment Korea
2 deals together
Chong Kun Dang
1 deal together
Consensus Business Group
1 deal together
Daelim Corporation
1 deal together
Dayli Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chong Kun Dang Pharmaceutical Corp. invest in?
Chong Kun Dang Pharmaceutical Corp. invests primarily in Health Care, Therapeutics and FinTech startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chong Kun Dang Pharmaceutical Corp. last invest?
The most recent investment recorded for Chong Kun Dang Pharmaceutical Corp. closed in Feb 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
